Table 1.

Pharmacological summary for logEC50 of dose–response curves in Figure 5 and Figure 6.

		EC50
Figure 5		1:0	1:3	1:6
A	zMc4r:RMrap2a (α-MSH)	1.51 × 10−9 [±1.06 × 10−9]	4.01 × 10−10 ns [±2.49 $\times$ 10−10]	6.62 × 10−11 *** [±9.93 $\times$ 10−11]
B	zMc4r:RMrap2b (α-MSH)	1.23 × 10−9 [±0.55 × 10−9]	9.42 $\times$ 10−10 * [±11.80 $\times$ 10−10]	1.28 $\times$ 10−9 *** [±1.56 $\times$ 10−9]
C	mMC4R:RMRAP2 (α-MSH)	5.79 $\times$ 10−9 [±2.83 $\times$ 10−9]	5.47 $\times$ 10−9 ns [±2.06 $\times$ 10−9]	7.46 $\times$ 10−9 ns [±5.43 $\times$ 10−9]
D	zMc4r:RMrap2a (SHU9119)	1.04 $\times$ 10−8 [±0.67 $\times$ 10−8]	6.97 $\times$ 10−9 *** [±5.21 $\times$ 10−9]	8.59 $\times$ 10−9 *** [±10.16 $\times$ 10−9]
E	zMc4r:RMrap2b (SHU9119)	1.11 $\times$ 10−8 [±0.75 $\times$ 10−8]	1.80 $\times$ 10−8 ns [±1.74 $\times$ 10−8]	7.68 $\times$ 10−9 ** [±6.31 $\times$ 10−9]
F	mMC4R:RMRAP2 (SHU9119)	8.17 $\times$ 10−11 [±6.02 $\times$ 10−11]	8.37 $\times$ 10−11 ns [±11.60 $\times$ 10−11]	4.20 $\times$ 10−11 ns [±11.56 $\times$ 10−11]
Figure 6		1:0:0	1:2:4	1:3:3	1:4:2
A	zMc4r:Mrap2a:RMrap2a (α-MSH)	2.60 $\times$ 10−9 [±1.74 $\times$ 10−9]	5.26 $\times$ 10−10 ns [±3.01 $\times$ 10−10]	8.17 $\times$ 10−10 ns [±2.61 $\times$ 10−10]	1.07 $\times$ 10−9 ns [±0.37 $\times$ 10−9]
B	zMc4r:Mrap2b:RMrap2b (α-MSH)	9.44 $\times$ 10−10 [±6.12 $\times$ 10−10]	3.60 $\times$ 10−10 * [±4.00 $\times$ 10−10]	3.02 $\times$ 10−10 * [±3.73 $\times$ 10−10]	2.50 $\times$ 10−10 * [±3.02 $\times$ 10−9]
C	mMC4R:MRAP2:RMRAP2 (α-MSH)	6.48 $\times$ 10−9 [±4.15 $\times$ 10−9]	1.62 $\times$ 10−8 ns [±1.91 $\times$ 10−8]	2.81 $\times$ 10−8 ** [±3.43 $\times$ 10−8]	2.41 $\times$ 10−8 ns [±12.62 $\times$ 10−8]
D	zMc4r:Mrap2a:RMrap2a (SHU9119)	1.23 $\times$ 10−8 [±1.42 $\times$ 10−8]	1.30 $\times$ 10−8 ns [±0.55 $\times$ 10−8]	9.03 $\times$ 10−9 * [±3.97 $\times$ 10−9]	7.53 $\times$ 10−9 * [±3.16 $\times$ 10−9]
E	zMc4r:Mrap2b:RMrap2b (SHU9119)	8.78 $\times$ 10−9 [±11.20 $\times$ 10−9]	2.87 $\times$ 10−9 *** [±4.11 $\times$ 10−9]	3.85 $\times$ 10−9 *** [±3.40 $\times$ 10−9]	3.99 $\times$ 10−9 *** [±2.01 $\times$ 10−9]
F	mMC4R:MRAP2:RMRAP2 (SHU9119)	2.49 $\times$ 10−9 [±3.05 $\times$ 10−9]	1.02 $\times$ 10−9 ns [±0.39 $\times$ 10−9]	5.47 $\times$ 10−10 ns [±2.29 $\times$ 10−10]	3.83 $\times$ 10−10 ns [±1.37 $\times$ 10−10]

Data shown in Table 1 represent the EC50 of dose–response curves in Figure 5 and Figure 6. Numbers in brackets are with the 95% confidence intervals of nonlinear fittings. One-way ANOVA and Tukey post-tests were employed to measure the significance between the MC4R expression alone group (1:0) and the experimental groups. ns (not significant difference), * p < 0.05, ** p < 0.01, *** p < 0.001.